Congress moves to revoke FDA approval of abortion pill nationwide
H.R. 795 — Pregnancy Is Not an Illness Act of 2025 · Filed by Mary Miller (R-IL) · 11 cosponsors · Introduced Jan 28, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits the FDA from approving or regulating abortion drugs by treating pregnancy as a medical condition. It nullifies the existing FDA approval of mifepristone (the abortion pill) and any other abortion drug approval that relied on pregnancy being classified as an illness requiring medical treatment.
Why we flagged it
The bill's operative mechanism is to block FDA approval pathways and nullify an existing drug approval. It is framed as a definitional matter (pregnancy is not an illness) but functions as a direct prohibition on a specific medication's federal authorization.
What the text implies
- The bill does not ban abortion itself or state-level regulation of abortion; it removes federal regulatory authorization. States that have not independently banned mifepristone may face a gap between state law (which may permit abortion) and federal law (which would withdraw the drug's approval), creating legal uncertainty for providers and patients.
- The nullification of mifepristone's existing approval is retroactive—it voids a decision made under prior administrations and prior FDA scientific review. This sets a precedent for Congress to override FDA drug approvals by legislative fiat rather than through the standard safety/efficacy review process.
- The bill's language ('treating pregnancy as illness') reframes a regulatory classification (pregnancy as a medical condition requiring medical management) as a policy choice rather than a scientific or medical fact. This may signal intent to restrict FDA's ability to regulate other pregnancy-related medications or conditions.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill removes federal regulatory authorization for mifepristone, a medication used in approximately half of U.S. abortions. Citizens—particularly those in states without state-level bans—lose access to a medication the FDA previously determined safe and effective. The bill does not expand access to any alternative; it restricts an existing option.
Named in the bill
Department of Health and Human Services, Food and Drug Administration (FDA), mifepristone, Federal Food, Drug, and Cosmetic Act, section 505, section 505-1
Where it stands
11 cosponsors: 11 Republicans.
- Jan 28, 2025 — Introduced · Congress.gov: “Introduced in House”
- Jan 28, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $420,000 in lobbying spend. A filing names 51 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Mary Miller, the sponsor, reported $145,130 in PAC receipts in the 2026 cycle.
- Susan B Anthony List — $420,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,099 characters) on Sep 28, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress moves to revoke FDA approval of abortion pill nationwide” QuorumCivic. https://share.quorumcivic.app/bill/119/hr795 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.